Cytotoxic Activity of Immunotoxin SS1P is Modulated by TACE-dependent Mesothelin Shedding

Overview

Journal Cancer Res

Specialty Oncology

Date 2011 Jul 22

PMID 21775520

Citations 28

Authors

Yujian Zhang

Oleg Chertov

Jingli Zhang

Raffit Hassan

Ira Pastan

Affiliations

Soon will be listed here.

Abstract

Mesothelin is a cell-surface tumor-associated antigen expressed in several human cancers. The limited expression of mesothelin on normal tissues and its high expression in many cancers make it an attractive candidate for targeted therapies using monoclonal antibodies, immunoconjugates, and immunotoxins. Mesothelin is actively shed from the cell surface and is present in the serum of patients with malignant mesothelioma, which could negatively affect the response to these therapies. We have found that mesothelin sheddase activity is mediated by a TNF-α converting enzyme (TACE), a member of the matrix metalloproteinase/a disintegrin and metalloprotease family. We showed that EGF and TIMP-3 act through TACE as endogenous regulators of mesothelin shedding. We also found that reducing shedding significantly improved the in vitro cytotoxicity of immunotoxin SS1P, which targets mesothelin and is currently in clinical trials for the treatment of patients with mesothelioma and lung cancer. Our findings provide a mechanistic understanding of mesothelin shedding and could help improve mesothelin-based targeted therapies.

Citing Articles

Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma.

Mansfield A, Vivien Yin J, Bradbury P, Kwiatkowski D, Patel S, Bazhenova L Lung Cancer. 2024; 195:107928.

PMID: 39197359 PMC: 11416719. DOI: 10.1016/j.lungcan.2024.107928.

T cell-redirecting antibody for treatment of solid tumors via targeting mesothelin.

Liu J, Pan Z, Yue Y, Wang S, Chen J, Jiang H Acta Pharmacol Sin. 2024; 45(10):2186-2198.

PMID: 38858494 PMC: 11420237. DOI: 10.1038/s41401-024-01316-6.

A bispecific antibody that targets the membrane-proximal region of mesothelin and retains high anticancer activity in the presence of shed mesothelin.

Chakraborty A, Onda M, OShea T, Wei J, Liu X, Bera T Mol Cancer Ther. 2024; .

PMID: 38647528 PMC: 11493849. DOI: 10.1158/1535-7163.MCT-23-0233.

Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope.

Liu X, Onda M, Schlomer J, Bassel L, Kozlov S, Tai C Proc Natl Acad Sci U S A. 2024; 121(4):e2317283121.

PMID: 38227666 PMC: 10823246. DOI: 10.1073/pnas.2317283121.

Breast cancer immunopeptidomes contain numerous shared tumor antigens.

Kina E, Laverdure J, Durette C, Lanoix J, Courcelles M, Zhao Q J Clin Invest. 2023; 134(1).

PMID: 37906288 PMC: 10760959. DOI: 10.1172/JCI166740.

References

Tellier E, Canault M, Rebsomen L, Bonardo B, Juhan-Vague I, Nalbone G . The shedding activity of ADAM17 is sequestered in lipid rafts. Exp Cell Res. 2006; 312(20):3969-80. DOI: 10.1016/j.yexcr.2006.08.027. View

Zhou B, Peyton M, He B, Liu C, Girard L, Caudler E . Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell. 2006; 10(1):39-50. PMC: 4451119. DOI: 10.1016/j.ccr.2006.05.024. View

Arribas J, Esselens C . ADAM17 as a therapeutic target in multiple diseases. Curr Pharm Des. 2009; 15(20):2319-35. DOI: 10.2174/138161209788682398. View

Zhang Y, Hansen J, Xiang L, Kawa S, Onda M, Ho M . A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptake. Cancer Res. 2010; 70(3):1082-9. PMC: 2818704. DOI: 10.1158/0008-5472.CAN-09-2405. View

Esselens C, Malapeira J, Colome N, Moss M, Canals F, Arribas J . Metastasis-associated C4.4A, a GPI-anchored protein cleaved by ADAM10 and ADAM17. Biol Chem. 2008; 389(8):1075-84. DOI: 10.1515/bc.2008.121. View

Borrell-Pages M, Rojo F, Albanell J, Baselga J, Arribas J . TACE is required for the activation of the EGFR by TGF-alpha in tumors. EMBO J. 2003; 22(5):1114-24. PMC: 150344. DOI: 10.1093/emboj/cdg111. View

Ordonez N . Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol. 2003; 27(11):1418-28. DOI: 10.1097/00000478-200311000-00003. View

Sapede C, Gauvrit A, Barbieux I, Padieu M, Cellerin L, Sagan C . Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells. Cancer Sci. 2008; 99(3):590-4. PMC: 11158685. DOI: 10.1111/j.1349-7006.2007.00715.x. View

Nuti E, Tuccinardi T, Rossello A . Matrix metalloproteinase inhibitors: new challenges in the era of post broad-spectrum inhibitors. Curr Pharm Des. 2007; 13(20):2087-100. DOI: 10.2174/138161207781039706. View

10.

Brew K, Nagase H . The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta. 2010; 1803(1):55-71. PMC: 2853873. DOI: 10.1016/j.bbamcr.2010.01.003. View

11.

Chang K, Pastan I . Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A. 1996; 93(1):136-40. PMC: 40193. DOI: 10.1073/pnas.93.1.136. View

12.

Zhang Y, Xiang L, Hassan R, Pastan I . Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors. Proc Natl Acad Sci U S A. 2007; 104(43):17099-104. PMC: 2040446. DOI: 10.1073/pnas.0708101104. View

13.

Chang K, Pastan I . Molecular cloning and expression of a cDNA encoding a protein detected by the K1 antibody from an ovarian carcinoma (OVCAR-3) cell line. Int J Cancer. 1994; 57(1):90-7. DOI: 10.1002/ijc.2910570117. View

14.

Thiel K, Carpenter G . ErbB-4 and TNF-alpha converting enzyme localization to membrane microdomains. Biochem Biophys Res Commun. 2006; 350(3):629-33. PMC: 1637093. DOI: 10.1016/j.bbrc.2006.09.095. View

15.

Leao I, Ganesan P, Armstrong T, Jaffee E . Effective depletion of regulatory T cells allows the recruitment of mesothelin-specific CD8 T cells to the antitumor immune response against a mesothelin-expressing mouse pancreatic adenocarcinoma. Clin Transl Sci. 2010; 1(3):228-39. PMC: 2847413. DOI: 10.1111/j.1752-8062.2008.00070.x. View

16.

Hassan R, Bullock S, Premkumar A, Kreitman R, Kindler H, Willingham M . Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res. 2007; 13(17):5144-9. DOI: 10.1158/1078-0432.CCR-07-0869. View

17.

Santiago-Josefat B, Esselens C, Bech-Serra J, Arribas J . Post-transcriptional up-regulation of ADAM17 upon epidermal growth factor receptor activation and in breast tumors. J Biol Chem. 2007; 282(11):8325-31. DOI: 10.1074/jbc.M608826200. View

18.

Vincent B, Paitel E, Saftig P, Frobert Y, Hartmann D, De Strooper B . The disintegrins ADAM10 and TACE contribute to the constitutive and phorbol ester-regulated normal cleavage of the cellular prion protein. J Biol Chem. 2001; 276(41):37743-6. DOI: 10.1074/jbc.M105677200. View

19.

Carpenito C, Milone M, Hassan R, Simonet J, Lakhal M, Suhoski M . Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A. 2009; 106(9):3360-5. PMC: 2651342. DOI: 10.1073/pnas.0813101106. View

20.

Zhang Y, Xiang L, Hassan R, Paik C, Carrasquillo J, Jang B . Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice. Clin Cancer Res. 2006; 12(15):4695-701. DOI: 10.1158/1078-0432.CCR-06-0346. View